Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Breast cancer in 2010: Novel targets and therapies for a personalized approach.

Literature DB >> 21278769

Breast cancer in 2010: Novel targets and therapies for a personalized approach.

Abstract

2010 has been another prolific year in breast cancer research with a number of original observations bringing us closer to personalized care. Studies with novel targeted agents in defined breast cancer subgroups have revealed exciting developments and highlight the importance of patient selection.

Entities: Disease Species

Mesh：

Year: 2011 PMID： 21278769 DOI： 10.1038/nrclinonc.2010.217

Source DB: PubMed Journal: Nat Rev Clin Oncol ISSN： 1759-4774 Impact factor: 66.675

8 in total

1. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.

Authors: Ian E Krop; Muralidhar Beeram; Shanu Modi; Suzanne F Jones; Scott N Holden; Wei Yu; Sandhya Girish; Jay Tibbitts; Joo-Hee Yi; Mark X Sliwkowski; Fred Jacobson; Stuart G Lutzker; Howard A Burris
Journal: J Clin Oncol Date: 2010-04-26 Impact factor: 44.544

2. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

Authors: Howard A Burris; Hope S Rugo; Svetislava J Vukelja; Charles L Vogel; Rachel A Borson; Steven Limentani; Elizabeth Tan-Chiu; Ian E Krop; Richard A Michaelson; Sandhya Girish; Lukas Amler; Maoxia Zheng; Yu-Waye Chu; Barbara Klencke; Joyce A O'Shaughnessy
Journal: J Clin Oncol Date: 2010-12-20 Impact factor: 44.544

3. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

Authors: M William Audeh; James Carmichael; Richard T Penson; Michael Friedlander; Bethan Powell; Katherine M Bell-McGuinn; Clare Scott; Jeffrey N Weitzel; Ana Oaknin; Niklas Loman; Karen Lu; Rita K Schmutzler; Ursula Matulonis; Mark Wickens; Andrew Tutt
Journal: Lancet Date: 2010-07-06 Impact factor: 79.321

4. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

Authors: Andrew Tutt; Mark Robson; Judy E Garber; Susan M Domchek; M William Audeh; Jeffrey N Weitzel; Michael Friedlander; Banu Arun; Niklas Loman; Rita K Schmutzler; Andrew Wardley; Gillian Mitchell; Helena Earl; Mark Wickens; James Carmichael
Journal: Lancet Date: 2010-07-06 Impact factor: 79.321

5. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

Authors: David W Miles; Arlene Chan; Luc Y Dirix; Javier Cortés; Xavier Pivot; Piotr Tomczak; Thierry Delozier; Joo Hyuk Sohn; Louise Provencher; Fabio Puglisi; Nadia Harbeck; Guenther G Steger; Andreas Schneeweiss; Andrew M Wardley; Andreas Chlistalla; Gilles Romieu
Journal: J Clin Oncol Date: 2010-05-24 Impact factor: 44.544

6. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.

Authors: José Baselga; Karen A Gelmon; Shailendra Verma; Andrew Wardley; Pierfranco Conte; David Miles; Giulia Bianchi; Javier Cortes; Virginia A McNally; Graham A Ross; Pierre Fumoleau; Luca Gianni
Journal: J Clin Oncol Date: 2010-02-01 Impact factor: 44.544

7. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.

Authors: Kathy S Albain; William E Barlow; Steven Shak; Gabriel N Hortobagyi; Robert B Livingston; I-Tien Yeh; Peter Ravdin; Roberto Bugarini; Frederick L Baehner; Nancy E Davidson; George W Sledge; Eric P Winer; Clifford Hudis; James N Ingle; Edith A Perez; Kathleen I Pritchard; Lois Shepherd; Julie R Gralow; Carl Yoshizawa; D Craig Allred; C Kent Osborne; Daniel F Hayes
Journal: Lancet Oncol Date: 2009-12-10 Impact factor: 41.316

8. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

Authors: Kathy Miller; Molin Wang; Julie Gralow; Maura Dickler; Melody Cobleigh; Edith A Perez; Tamara Shenkier; David Cella; Nancy E Davidson
Journal: N Engl J Med Date: 2007-12-27 Impact factor: 91.245

8 in total

13 in total

1. The role of polycomb group protein Bmi-1 and Notch4 in breast cancer stem cell inhibition by benzyl isothiocyanate.

Authors: Su-Hyeong Kim; Shivendra V Singh
Journal: Breast Cancer Res Treat Date: 2015-02-08 Impact factor: 4.872

2. Suppression of FOXQ1 in benzyl isothiocyanate-mediated inhibition of epithelial-mesenchymal transition in human breast cancer cells.

Authors: Anuradha Sehrawat; Su-Hyeong Kim; Andreas Vogt; Shivendra V Singh
Journal: Carcinogenesis Date: 2012-12-30 Impact factor: 4.944

3. Aspirin blocks growth of breast tumor cells and tumor-initiating cells and induces reprogramming factors of mesenchymal to epithelial transition.

Authors: Gargi Maity; Archana De; Amlan Das; Snigdha Banerjee; Sandipto Sarkar; Sushanta K Banerjee
Journal: Lab Invest Date: 2015-04-13 Impact factor: 5.662

4. DNA damage and breast cancer.

Authors: Jennifer D Davis; Shiaw-Yih Lin
Journal: World J Clin Oncol Date: 2011-09-10

5. Single-nucleotide polymorphisms in DNA bypass polymerase genes and association with breast cancer and breast cancer subtypes among African Americans and Whites.

Authors: Leila Family; Jeannette T Bensen; Melissa A Troester; Michael C Wu; Carey K Anders; Andrew F Olshan
Journal: Breast Cancer Res Treat Date: 2014-11-23 Impact factor: 4.872